Imagine trying to test a new medicine but needing a biological 'twin' to see if it's safe. Currently, researchers often use monkeys, which is expensive and ethically difficult. This project creates a high-tech 'dictionary' and digital monitoring system to prove that specially bred pigs can do the job just as well, if not better.
Drug developers face high costs, ethical pressure, and regulatory hurdles when using non-human primates for safety testing. There is a critical lack of validated, human-like animal alternatives and digital tools to monitor them efficiently.
A multi-organ biobank of humanized minipigs, the iPig digital monitoring platform, and a FAIR database for cross-species biological data.
If you are a drug developer dealing with the high cost and ethical hurdles of primate testing — this project developed humanized pig models and a multi-omics database that provides a viable, regulatory-accepted alternative for safety assessment.
If you are an antibody therapy startup dealing with a lack of precise animal models for human antibodies — this project developed the humanised FcγR3B GMP model specifically for testing human antibodies.
If you are a biosensor manufacturer dealing with manual, labor-intensive data collection in animal trials — this project developed the iPig platform for automated digital monitoring and intelligent housing.
Based on available project data, specific pricing for the models or the iPig platform is not provided.
The project is currently in the development and validation phase, involving 32 partners to establish the scientific basis and biobanks for future industrial use.
Based on available project data, the project aims to build a FAIR, publicly accessible database, but specific licensing terms for the iPig platform are not listed.
The project has established a Regulatory Advisory Board to guide discussions and develop future standards for animal use in non-clinical safety testing.
The project runs from 2024-10-01 to 2029-09-30.
The consortium is heavily industry-driven with a 69% industry ratio, comprising 22 industrial partners including 6 SMEs. This strong commercial presence, spanning 12 countries and 32 total partners, indicates that the project is designed for direct integration into pharmaceutical R&D pipelines rather than remaining as academic research.
Contact Ludwig-Maximilians-Universität München
Contact us to explore how the iPig platform can optimize your safety assessment pipeline.
